Shares of the vaccine makers, including Moderna (MRNA), Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr Therapeutics (CRSP), are moving lower following the resignation of Peter Marks from the Food and Drug Administration. Marks was viewed as one of the biggest FDA advocates of cell and gene therapies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna (NASDAQ:MRNA) Leads U.S. Biotechs’ Plunge after FDA’s Top Vaccine Regulator Resigns
- Moderna receives TGA approval for mRESVIA in older adults
- U.S. to end funding for child vaccines in developing countries, NY Times reports
- Moderna price target lowered to $33 from $40 at JPMorgan
- Craig-Hallum bullish on Personalis, initiates with a Buy
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue